Parameter
| Biomarker | CDKN2A/B Homozygous Del | Full name | CDKN2A/B Homozygous Deletion | Molecular Type | Chromosomal Abnormality |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, Risk Stratification |
| Disease | Meningioma | Disease Subtypes | / | ||
| Organ | Brain, Meninges | Test Sample / Technology Platform | Tumor Tissue (FISH, CGH) | ||
| Pathobiological Mechanisms | Tumor suppressor gene deletion releases cell cycle regulation and promotes tumor proliferation. | ||||
| Clinical Availability Status | Under Clinical Validation | ||||
| Notes and Dynamics | Common in WHO Grade III meningiomas, indicating early recurrence risk; CDK4/6 inhibitors are a potential therapeutic direction. | ||||